Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + pazopanib before surgery for clear cell renal cell carcinoma with isolated lung metastases
ChiCTR2100049563Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab and pazopanib in clear cell renal cell carcinoma (ccRCC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Overall response rate. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
toripalimabpazopanib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on ChiCTR2100049563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049563.